跳转至内容
Merck

B7688

Sigma-Aldrich

PiB

≥98% (HPLC)

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C22H18N2O8
CAS号:
分子量:
438.39
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to light brown

溶解度

DMSO: 1-2 mg/mL (warmed)

儲存溫度

2-8°C

SMILES 字串

O=C(C1=C2C(C3=CC=C24)=C(C(N(CC(OCC)=O)C3=O)=O)C=C1)N(CC(OCC)=O)C4=O

InChI

1S/C22H18N2O8/c1-3-31-15(25)9-23-19(27)11-5-7-13-18-14(8-6-12(17(11)18)20(23)28)22(30)24(21(13)29)10-16(26)32-4-2/h5-8H,3-4,9-10H2,1-2H3

InChI 密鑰

WNKQGFNIIHNGQM-UHFFFAOYSA-N

生化/生理作用

PiB is an inhibitor of the peptidylprolyl isomerase Pin-1. Inhibition of Pin-1 leads to destabilization of the transcription factor Nanog, which is required for maintenance of embryonic stem cell cultures.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Nancy J Donovan et al.
Journal of Alzheimer's disease : JAD, 46(1), 63-73 (2015-02-24)
Even low levels of depressive symptoms are associated with an increased risk of cognitive decline in older adults without overt cognitive impairment (CN). Our objective was to examine whether very low, "subthreshold symptoms of depression" are associated with Alzheimer's disease
Christopher M Lee et al.
Journal of Alzheimer's disease : JAD, 62(4), 1691-1702 (2018-04-05)
On target 18F-Flortaucipir (FTP) binding of Alzheimer's disease tau aggregates and off-target binding of melanocytes have been demonstrated with autoradiography. We aimed to investigate the hypothesis that if binding in choroid plexus (CP) is due to melanocytes, the signal would
Jacob W Vogel et al.
Neurology, 89(19), 2002-2009 (2017-10-08)
To assess in a longitudinal study whether subjective cognitive decline (SCD) and brain β-amyloid (Aβ) contribute unique information to cognitive decline. One hundred thirty-six healthy elderly from the Berkeley Aging Cohort Study were followed up for a mean of 4
Jun Ho Lee et al.
Frontiers in aging neuroscience, 10, 309-309 (2018-10-20)
Background: Given the barriers prohibiting the broader utilization of amyloid imaging and high screening failure rate in clinical trials, an easily available and valid screening method for identifying cognitively impaired patients with cerebral amyloid deposition is needed. Therefore, we developed
Takamasa Yokoi et al.
Frontiers in aging neuroscience, 10, 304-304 (2018-10-23)
Background: Imaging studies in Alzheimer's disease (AD) have yet to answer the underlying questions concerning the relationship among tau retention, neuroinflammation, network disruption and cognitive decline. We compared the spatial retention patterns of 18F-THK5351 and resting state network (RSN) disruption

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门